Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
20s Proteasome - Pipeline Review, H2 2017 Summary According to the recently published report '20s Proteasome - Pipeline Review, H2 2017'; 20s Proteasome pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. 20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides. The report '20s Proteasome - Pipeline Review, H2 2017' outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Non Malignant Disorders and Women's Health which include indications Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Gynecological Cancer, Multiple Myeloma (Kahler Disease), Waldenstrom Macroglobulinemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyloidosis, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Endometriosis, Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Kidney Transplant Rejection, Lymphoma, Malignant Glioma, Mantle Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Renal Cell Carcinoma, Skin Cancer, Small-Cell Lung Cancer, Solid Tumor, T-Cell Lymphomas, Tuberculosis and Uterine Leiomyoma (Uterine Fibroids). Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for 20s Proteasome - The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects - The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to 20s Proteasome targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for 20s Proteasome - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 20s Proteasome - Overview 6 20s Proteasome - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 12 Products under Development by Universities/Institutes 16 20s Proteasome - Therapeutics Assessment 18 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 20s Proteasome - Companies Involved in Therapeutics Development 22 Amgen Inc 22 Celgene Corp 24 20s Proteasome - Drug Profiles 25 carfilzomib - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 marizomib - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 oprozomib - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecule to Inhibit 20s Proteasome for Tuberculosis - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 VPE-001 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 VPEA-002 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 VPEA-004 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 20s Proteasome - Dormant Products 50 20s Proteasome - Product Development Milestones 51 Featured News & Press Releases 51 Aug 30, 2017: FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS (Carfilzomib) Label 51 Aug 30, 2017: Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma 51 Aug 23, 2017: Overall Survival Analysis From KYPROLIS Phase 3 Endeavor Trial Published In The Lancet Oncology 52 Aug 08, 2017: Scottish Medicines Consortium Accepts Amgen's Multiple Myeloma Treatment, KYPROLIS (carfilzomib), in Combination with Dexamethasone, for use at First Relapse 53 Aug 07, 2017: Amgen's Kyprolis accepted for use in NHS Scotland 54 Jul 24, 2017: Novocure Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune as Adjuvant Therapy in Patients with Glioblastoma 54 Jul 19, 2017: NICE approves more tolerable treatment for blood cancer 55 Jul 14, 2017: Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS (Carfilzomib) Label 55 Jul 12, 2017: Second Phase 3 Study Shows KYPROLIS (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma 56 Jun 21, 2017: Amgen To Present New Data on KYPROLIS At 22nd Congress of the European Hematology Association 57 Jun 13, 2017: Amgen's Multiple Myeloma Treatment, KYPROLIS (Carfilzomib), in Combination with Dexamethasone, Receives NICE Recommendation for Use at First Relapse 57 May 18, 2017: ONO Receives Supplemental Manufacturing and Marketing Approval of KYPROLIS for Intravenous Injection 10 mg and 40 mg, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma 58 Mar 03, 2017: Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop 59 Mar 01, 2017: Amgen To Present New KYPROLIS (Carfilzomib) Data At The 16th International Myeloma Workshop 60 Feb 28, 2017: Phase 3 Head-to-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 61 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development by Stage of Development, H2 2017 7 Number of Products under Development by Therapy Areas, H2 2017 8 Number of Products under Development by Indications, H2 2017 10 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11 Number of Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 13 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15 Number of Products under Investigation by Universities/Institutes, H2 2017 16 Products under Investigation by Universities/Institutes, H2 2017 17 Number of Products by Stage and Mechanism of Actions, H2 2017 18 Number of Products by Stage and Route of Administration, H2 2017 20 Number of Products by Stage and Molecule Type, H2 2017 21 Pipeline by Amgen Inc, H2 2017 23 Pipeline by Celgene Corp, H2 2017 24 Dormant Projects, H2 2017 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
